[logo] HealthTree Foundation
more_vert
close
person Sign In / Create Account

What are BTK Inhibitors?

What are BTK Inhibitors? image

What are BTK Inhibitors?

Webinar
event Aug 13, 2025 / 01:30PM - 02:30PM EDT
link icon facebook logo X logo linkedin logo reddit logo email icon
videocam
Can't make it to the event?
We send a recording to all registered participants of the event!

Event Description

Join HealthTree for this webinar focusing on learning more about the family of therapies known as BTK Inhibitors which includes ibrutinib, acalabrutinib, zanubrutinib and pirtobrutinib.

 

 

Schedule & Agenda

The panelist Dalton Bean
1:30 PM
Introduction
Dalton Bean

Dalton introduces the agenda of the event and featured speaker John Allan MD

The panelist John Allan MD
1:35 PM
Presentation
John Allan MD

Dr. Allan talks about BTK inhibitors

The panelist Dalton Bean
2:05 PM
Questions and Answers
Dalton Bean

Type your questions in the chat, we will answer them!

Speakers & Moderators

The panelist Dalton Bean
Dalton Bean
Lehi, UT

Dalton joined HealthTree in 2024 as the CLL and MF Education Manager. He is passionate about helping patients gain a better understanding of their health and treatment and sees it as a way to help empower individuals and their families who are affected by these diseases. Prior to joining HealthTree Dalton earned a Master’s Degree in Oncological Sciences while studying various different blood cancers. When not interacting with patients he is an avid snowboarder and hiker.

Read Bio
The panelist John Allan MD
John Allan MD

Dr. Allan is an Associate Professor of Clinical Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine. Dr. Allan completed his undergraduate education at the University of Missouri-Columbia and graduated with a B.S. in both Biochemistry and Finance. He subsequently obtained his medical degree from Saint Louis University. Seeking an internal medicine residency program with particular strength in oncology, Dr. Allan moved to New York in 2009 to train at NewYork-Presbyterian Hospital, Weill Cornell Medical Campus, where he also completed his hematology and medical oncology fellowship. Upon completion of training Dr. Allan joined the lymphoma faculty in the Division of Hematology and Oncology and is a member of the CLL Research Center.  Dr. Allan treats all lymphoid malignancies and has a particular interest in improving therapies for patients with CLL and Richter’s Syndrome, which is the focus of his research. 

Read Bio
HealthTree Connect Icon

Join the Conversation

This event is part of the Treatments & Drugs group in HealthTree Connect, a social media platform for people with blood cancer. If you want to connect with other patients and caregivers and talk about this topic, join HealthTree Connect.

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

All HealthTree resources available anywhere, anytime
Download our App
Download iOS App Download Android App
iphone app mockup
newsletter icon

Get the Latest Chronic Lymphocytic Leukemia Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.